Last reviewed · How we verify
SHR2150 tablet、efavirenz — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
SHR2150 tablet、efavirenz (SHR2150 tablet、efavirenz) — Jiangsu HengRui Medicine Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SHR2150 tablet、efavirenz TARGET | SHR2150 tablet、efavirenz | Jiangsu HengRui Medicine Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SHR2150 tablet、efavirenz CI watch — RSS
- SHR2150 tablet、efavirenz CI watch — Atom
- SHR2150 tablet、efavirenz CI watch — JSON
- SHR2150 tablet、efavirenz alone — RSS
Cite this brief
Drug Landscape (2026). SHR2150 tablet、efavirenz — Competitive Intelligence Brief. https://druglandscape.com/ci/shr2150-tablet-efavirenz. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab